Filing Flows

Filing Flows › Arcutis Biotherapeutics (ARQT) › Next earnings date

Arcutis Biotherapeutics (ARQT) earnings: missed the estimate

Arcutis Biotherapeutics (ARQT) reported on Nov 4, 2026 and missed the EPS estimate: $0.06 against $0.17 (-64.4%). Revenue was $144M for Q3 2026, +45% year over year. It beat the EPS estimate in 60% of the quarters on record.

Last result−64.4% vs estimate
Beat rate60%

The last report

Arcutis Biotherapeutics reported revenue of $144M for the third quarter 2026 (+45% Y/Y), net earnings $8.8M: ZORYVE foam $75.1M, ZORYVE cream 0.3% $37.8M, ZORYVE cream 0.15% $27.3M, ZORYVE cream 0.05% $3.7M. How it makes money → · Every quarter →

Arcutis Biotherapeutics: EPS against the estimate, last 5 reportsArcutis Biotherapeutics: EPS against the estimate, last 5 reportsEstimateReported−$0.09$0.06Oct 25$0.09$0.13Feb 26−$0.06−$0.09May 26$0.05$0.11Aug 26$0.17$0.06Nov 26
Latest (Nov 26): Estimate $0.17, Reported $0.06.

Arcutis Biotherapeutics' latest quarter

Arcutis Biotherapeutics, Q3 2026: revenue $144M (+45% year over year), operating margin 6.6%, net earnings $8.8M, operating cash flow $18.9M. The chart follows the revenue to costs, profit and cash.

Questions

Did Arcutis Biotherapeutics beat earnings?

Arcutis Biotherapeutics (ARQT) reported on Nov 4, 2026 and missed the EPS estimate: $0.06 against $0.17 (-64.4%).

When does ARQT report earnings?

The next date is not set yet.

Does Arcutis Biotherapeutics usually beat earnings?

It beat the consensus EPS estimate in 60% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.